COMPANY PROFILE

PLAQUETEC

Explore full profile

Biomarker platform for coronary artery disease precision medicine

Cambridge, United KingdomFounded 2008Biotech & Life Sciences

Valuation $25–50M Last recorded · 2026

Revenue <$1M Latest reported FY

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About PLAQUETEC

PlaqueTec was formed in 2008 within Papworth Hospital in Cambridge (UK), as a spinout from PA Consulting. With funding from IPEX Capital and guidance from a strong network of scientific advisors and clinicians, the company has developed the first-of-its-kind PlaqueTec Liquid Biopsy Systemâ¢ (LBS), a platform technology that enables unparalleled resolution of the processes that lead to coronary artery disease (CAD). Since 2012, PlaqueTec has validated its LBS device in two clinical studies and identified numerous biomarkers that are associated with CAD. The company is using these biomarkers to build a database to provide a better understanding of CAD that can be used by clinicians, researchers, and biopharmaceutical companies to conduct translational research and develop next-generation personalized therapies. The PlaqueTec LBS received a CE Mark in July 2014 for use in the EU.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2008
Headquarters: Cambridge, United Kingdom
Employees: 4
Open positions: None listed
Dealroom signal: 34.6/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biomarkers, Cardiology and cardiovascular, Precision Medicine, DT and LS, uk is8 life sciences, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VC✓Equity / VC	Apr 2026	$5M	$40M	Undisclosed	↗
LATE VC✓Equity / VC	Apr 2024	$8M	$32M	Future Fund	↗

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	EBITDA	Margin	Profit	Margin
2026
2025
2024
2023
2022
2021
2020		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

PLAQUETEC website traffic

Latest recorded traffic for PLAQUETEC is 130 monthly website visits, down 81.7% over the last three months. PLAQUETEC's team grew 0% over the past year.

Latest monthly visits130 3-month web change-81.7% 1-year team growth0%

Monthly website visitsOct 2020–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
AVAverywellAI-powered liquid biopsy for early lung cancer detection	Manchester, United Kingdom	Operational	3	—	—
MTMonument TherapeuticsPrecision neuroscience drugs for central nervous system diseases	Macclesfield, United Kingdom	Operational
CACase45AI-powered biomarkers for personalised cancer therapies	London, United Kingdom	Operational
TATagomicsMultiomic platform for disease biomarker discovery and diagnostics	Cambridge, United Kingdom	Operational
GLGlycanAgeOffers an at-home biological age testing kit that analyzes blood samples and provides personalized wellness advice to increase longevity	Newcastle upon Tyne, United Kingdom	Operational
BIBiofidelityRapid genomic biomarker detection for precision oncology	Cambridge, United Kingdom	Operational
SUSurgeInnovative fingerprinting of the immune system with AI to holistically improve the perioperative standard-of-care	Paris, France	Operational
OMOmicsChartPatient-centric cancer data and analytics platform for translational cancer biologists	Cardiff, United Kingdom	Operational